Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferenc Oberfrank

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Value in Health Regional Issues|April 29, 2018
The Role of the National Health Insurance Fund Administration in the Development of Health Economics and Health Technology Assessment in HungaryFerenc Oberfrank
Magyar Sebeszet|December 5, 2025
Ferenc Oberfrank, Tamás Freund
Orvosi Hetilap|November 10, 2015
[Applicability of hospital reports submitted for reimbursement purposes for epidemiological studies based on the example of ischemic cerebrovascular diseases]András Ajtay, Ferenc Oberfrank, Dániel Bereczki
Acta Pharmaceutica Hungarica|July 5, 2013
[The influence of pharmacoeconomic laws on pharmacies between 2007-2010 in Hungary]Imre Boncz, Verebes Eva Donkáné, Ferenc Oberfrank
Magyar Onkologia|December 18, 2010
[Assessment of annual health insurance reimbursement for oncology drugs in Hungary]Imre Boncz, Eva Donkáné Verebes, Ferenc Oberfrank, et al.
Magyar Onkologia|March 31, 2010
[Health-economics of oncology care: changes in hospital bed capacity]Imre Boncz, Eva Donka-Verebes, Ferenc Oberfrank, et al.
Magyar Onkologia|March 31, 2010
[Health economics of oncology care: financial effect of performance volume limit (PVL)]Imre Boncz, Eva Donkáné Verebes, Ferenc Oberfrank, et al.
Ideggyogyaszati Szemle|December 2, 2020
[The connection between the socioeconomic status and stroke in Budapest]Ildikó Vastagh, Ildikó Szőcs, Ferenc Oberfrank, et al.
Plos One|August 5, 2020
The prevalence of psychiatric symptoms before the diagnosis of Parkinson's disease in a nationwide cohort: A comparison to patients with cerebral infarctionSzabolcs Szatmári, András Ajtay, Ferenc Oberfrank, et al.
Geroscience|October 16, 2021
Cholinesterase inhibitors for the treatment of dementia: real-life data in HungaryNóra Balázs, Dániel Bereczki, András Ajtay, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Value in Health Regional Issues|April 29, 2018
The Role of the National Health Insurance Fund Administration in the Development of Health Economics and Health Technology Assessment in HungaryFerenc Oberfrank
Magyar Sebeszet|December 5, 2025
Ferenc Oberfrank, Tamás Freund
Orvosi Hetilap|November 10, 2015
[Applicability of hospital reports submitted for reimbursement purposes for epidemiological studies based on the example of ischemic cerebrovascular diseases]András Ajtay, Ferenc Oberfrank, Dániel Bereczki
Acta Pharmaceutica Hungarica|July 5, 2013
[The influence of pharmacoeconomic laws on pharmacies between 2007-2010 in Hungary]Imre Boncz, Verebes Eva Donkáné, Ferenc Oberfrank
Magyar Onkologia|December 18, 2010
[Assessment of annual health insurance reimbursement for oncology drugs in Hungary]Imre Boncz, Eva Donkáné Verebes, Ferenc Oberfrank, et al.
Magyar Onkologia|March 31, 2010
[Health-economics of oncology care: changes in hospital bed capacity]Imre Boncz, Eva Donka-Verebes, Ferenc Oberfrank, et al.
Magyar Onkologia|March 31, 2010
[Health economics of oncology care: financial effect of performance volume limit (PVL)]Imre Boncz, Eva Donkáné Verebes, Ferenc Oberfrank, et al.
Ideggyogyaszati Szemle|December 2, 2020
[The connection between the socioeconomic status and stroke in Budapest]Ildikó Vastagh, Ildikó Szőcs, Ferenc Oberfrank, et al.
Plos One|August 5, 2020
The prevalence of psychiatric symptoms before the diagnosis of Parkinson's disease in a nationwide cohort: A comparison to patients with cerebral infarctionSzabolcs Szatmári, András Ajtay, Ferenc Oberfrank, et al.
Geroscience|October 16, 2021
Cholinesterase inhibitors for the treatment of dementia: real-life data in HungaryNóra Balázs, Dániel Bereczki, András Ajtay, et al.
Pageof 2